Index by author

Intra-arterial chemotherapy (IAC) for retinoblastoma (Rb) has dramatically altered the natural history of the disease. Cure rates, globe salvage, and vision preservation have dramatically increased. This retrospective chart review evaluated 207 Rb tumors of 207 eyes in 196 consecutive patients who underwent 658 IAC infusions overall. Patient weights were ≤10 kg in 69 (35.2%) and >10 kg in 127 (64.8%) patients. Comparison (≤10 kg versus >10 kg) revealed that the total number of IAC infusions was 222 versus 436. Periprocedural complications were not significantly different. The authors conclude that intra-arterial chemotherapy in patients weighing ≤10 kg is a safe and effective treatment.

The authors performed a retrospective data base search that queried neck CT reports with Neck Imaging Reporting and Data Systems scores of 2–4 from June 2014 to March 2018. The electronic medical records were reviewed to determine outcomes of clinical and radiologic follow-up, including symptoms, physical examination findings, pathologic correlation, and clinical notes within 3 months of imaging. A total of 255 cases all with NIRADS scores of 2 or 3 met the inclusion criteria. Fifty-nine patients (23%) demonstrated recurrence, and 21 patients (36%) had clinically occult recurrence. The median overall time to radiologically detected, clinically occult recurrence was 11.4 months from treatment completion. They conclude that imaging surveillance beyond the first posttreatment baseline study was critical for detecting clinically occult recurrent disease in patients with head and neck squamous cell carcinoma. More than one-third of all recurrences were seen in patients without clinical evidence of disease.